CN104207130B - A kind of food of clearing heat and freeing strangury, health products or pharmaceutical composition - Google Patents
A kind of food of clearing heat and freeing strangury, health products or pharmaceutical composition Download PDFInfo
- Publication number
- CN104207130B CN104207130B CN201410472914.8A CN201410472914A CN104207130B CN 104207130 B CN104207130 B CN 104207130B CN 201410472914 A CN201410472914 A CN 201410472914A CN 104207130 B CN104207130 B CN 104207130B
- Authority
- CN
- China
- Prior art keywords
- food
- health products
- pharmaceutical composition
- raw material
- clearing heat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 206010042170 Strangury Diseases 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 19
- 240000001579 Cirsium arvense Species 0.000 claims abstract description 19
- 235000005918 Cirsium arvense Nutrition 0.000 claims abstract description 19
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 19
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 19
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 19
- 240000003915 Lophatherum gracile Species 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 241000894006 Bacteria Species 0.000 claims abstract description 10
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 7
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 7
- 241000194017 Streptococcus Species 0.000 claims abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 7
- 230000002949 hemolytic effect Effects 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 235000013361 beverage Nutrition 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000007598 dipping method Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 7
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 238000011109 contamination Methods 0.000 abstract description 4
- 230000002485 urinary effect Effects 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 20
- 238000012360 testing method Methods 0.000 description 14
- 206010014025 Ear swelling Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000008961 swelling Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 208000019206 urinary tract infection Diseases 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000050051 Chelone glabra Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 201000007094 prostatitis Diseases 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- KVYRCBOUKXJXDK-UHFFFAOYSA-N 3,4-dimethylphenazine-1,2-diamine hydrochloride Chemical compound Cl.C1=CC=CC2=NC3=C(C)C(C)=C(N)C(N)=C3N=C21 KVYRCBOUKXJXDK-UHFFFAOYSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- -1 sorbierite Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WBDGLSGKTWAWHK-UHFFFAOYSA-N 2,3-dibutylbenzoic acid Chemical compound CCCCC1=CC=CC(C(O)=O)=C1CCCC WBDGLSGKTWAWHK-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000853 cresyl group Chemical class C1(=CC=C(C=C1)C)* 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a kind of food of clearing heat and freeing strangury, health products or pharmaceutical composition, its raw material is containing, for example the component of lower weight proportion: cape jasmine 1 ~ 2 part, field thistle 1 ~ 2 part, lophatherum gracile 1 ~ 2 part, Honeysuckle flower 1 part, coix seed 1 ~ 1.5 part.Research shows, the present composition can effectively suppress the bacteriums such as staphylococcus aureus, hemolytic streptococcus or Pseudomonas aeruginosa, there is good antibacterial and anti-inflammatory activity, can be used for the treatment to urinary system infection contamination, and present composition compatibility is precise and appropriate, played synergy, drug activity is obviously better than each single raw material.
Description
Technical field
The present invention relates to a kind of food of clearing heat and freeing strangury, health products or pharmaceutical composition.
Background technology
Urinary system infection contamination is equivalent to heat pouring, blood beautiful jade, gas pouring, stranguria caused by overstrain etc. in traditional Chinese medical science stranguria, wherein heat is drenched in clinical the most common, it is a kind of common disease, frequently-occurring disease, the various age can be betided, maximum with Women of childbearing age, the incidence of disease of pregnant woman and girl baby is especially high, and the heat of girl baby is drenched the incidence of disease and be only second to respiratory infection diseases in infant infectious diseases; The male sex of more than 50 years old also has morbidity.
Heat drenches the illness such as acute and chronic prostatitis, prostatic hyperplasia, urgent, chronic nephropyeltis, cystitis, urethritis comprising modern medicine.Urinary tract infections is divided into upper urinary tract infection and lower urinary tract infection, is modal disease in the urological system, is also the modal infectious diseases of adult, mainly contains bacteriological infection and cause, and any bacterium invades and all can cause.
Due to prostatitis with urinary system infection contamination is many is caused by sensitive bacteria or pathogenic microorganism, thus doctor trained in Western medicine mainly with broad-spectrum antibiotic antibacterial be main.And the burnt damp-heat accumulation of differential diagnosis in tcm subordinate, functioning of bladder are unfavorable." all pathogeny marquis opinion " says: " Zhu Linzhe, the bladder heat by suffering from a deficiency of the kidney therefore also ... then urine number of suffering from a deficiency of the kidney, bladder heat is then puckery under water, several and puckery, then drippingly do not declare, therefore drenches for it ".Jing-Yue Complete Works is also said: " pouring for sick, then be invariably dissolved in popular drama, speechlessly debate ... have again and drench more than for a long time, all go so that pain is puckery, and cream liquid is endlessly, drenches as gonorrhoea person, this be the not solid card of the sinking of qi of middle-jiao and the gate of vitality also." due to the damp-heat accumulation part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels, cause disturbance in qi transformation, therefore see frequent micturition, urgent urination, odynuria.Waist is kidney mansion, and damp and hot heresy is invaded in kidney, and retardance meridian qi and blood is obstructed, causes pain in the back.Again because of damp-heat accumulation, heresy is orthogonal strives, so that the high heat of shiver with cold, and how rapid disease is rises.The traditional Chinese medical science is then the main rules for the treatment of with clearing heat and freeing strangury in treatment, covers content that is antibacterial in modern medicine and anti-inflammatory, compensate for western medicine and medical practitioners large to hepatorenal damage, only focuses on treatment and does not focus on repairing and the deficiency of immunity.
Summary of the invention
The object of the present invention is to provide a kind of food of clearing heat and freeing strangury, health products or pharmaceutical composition.
Particularly, the invention provides a kind of food of clearing heat and freeing strangury, health products or pharmaceutical composition, its raw material is containing, for example the component of lower weight proportion:
Cape jasmine 1 ~ 2 part, field thistle 1 ~ 2 part, lophatherum gracile 1 ~ 2 part, Honeysuckle flower 1 part, coix seed 1 ~ 1.5 part.
Further, its raw material is containing, for example the component of lower weight proportion:
Cape jasmine 1 part, field thistle 1.5 parts, lophatherum gracile 1.5 parts, Honeysuckle flower 1 part, coix seed 1.5 parts.
Further, its raw material is made up of the component of following weight proportion:
Cape jasmine 1 ~ 2 part, field thistle 1 ~ 2 part, lophatherum gracile 1 ~ 2 part, Honeysuckle flower 1 part, coix seed 1 ~ 1.5 part.
Further, its raw material is made up of the component of following weight proportion:
Cape jasmine 1 part, field thistle 1.5 parts, lophatherum gracile 1.5 parts, Honeysuckle flower 1 part, coix seed 1.5 parts.
Above-mentioned each raw material is integration of drinking and medicinal herbs material, namely can be used as medicine or health products use, also can be used as food and use.
Wherein, it be by the medicinal powder of raw material, water extract or/and ethanol extract is active component, add the oral administration formulation that pharmaceutically conventional auxiliary material or complementary composition are prepared from.
Such as, described formulation is selected from oral liquid, beverage, granule, powder, pill, tablet or capsule.
Pharmaceutically acceptable auxiliary material of the present invention, refer to the material be included in addition to the active ingredient (s in formulation, include but are not limited to filler (diluent), lubricant (glidant or antitack agent), dispersant, wetting agent, adhesive, conditioning agent, solubilizer, antioxidant, bacteriostatic agent, emulsifying agent, disintegrant etc.Adhesive comprises syrup, Arabic gum, gelatin, sorbierite, tragacanth, cellulose and its derivates (as microcrystalline cellulose, sodium carboxymethylcellulose, ethyl cellulose or HPMC etc.), gelatine size, syrup, starch slurry or polyvinylpyrrolidone etc.; Filler comprises lactose, Icing Sugar, dextrin, starch and derivative thereof, cellulose and its derivates, inorganic calcium salt (as calcium sulfate, calcium phosphate, calcium monohydrogen phosphate, precipitated calcium carbonate etc.), sorbierite or glycine etc.; Lubricant comprises superfine silica gel powder, dolomol, talcum powder, aluminium hydroxide, boric acid, hydrogenated vegetable oil, polyethylene glycol etc.; Disintegrant comprises starch and derivative (as sodium carboxymethyl starch, Explotab, pregelatinized starch, modified starch, hydroxypropul starch, cornstarch etc.), polyvinylpyrrolidone or microcrystalline cellulose etc.; Wetting agent comprises lauryl sodium sulfate, water or alcohol etc.; Antioxidant packages is containing sodium sulfite, sodium hydrogensulfite, sodium pyrosulfite, dibutyl benzoic acid etc.; Bacteriostatic agent comprises 0.5% phenol, 0.3% cresols, 0.5% anesin etc.; Conditioning agent comprises hydrochloric acid, citric acid, potassium hydroxide (sodium), sodium citrate and buffer (comprising sodium dihydrogen phosphate and sodium hydrogen phosphate) etc.; Emulsifier package is smooth containing Tween-80, aliphatic acid sorb, pluronic gram F-68, lecithin, Fabaceous Lecithin etc.; Solubilizer comprises Tween-80, bile, glycerine etc.
Described pharmaceutically acceptable complementary composition, it has certain physiologically active, but adding of this composition can not change above-claimed cpd or the leading position of derivative in treatment of diseases, and only play auxiliary effect, these auxiliary effects are only the utilizations to this composition known activity, are the usual adjuvant treatment modality of field of medicaments.If by above-mentioned complementary composition and the compounds of this invention with the use of, still should belong to the scope of protection of the invention.
Present invention also offers the preparation method of above-mentioned food, health products or pharmaceutical composition, it is characterized in that:
(1) raw material is taken by proportioning;
(2) by raw material extracting in water, Aqueous extracts is merged, preparation formulation.
Further, in step (2), described extracting method is selected from decoction, dipping or ultrasonic.
Water extract or be used as medicine with medicinal powder is all Chinese medicine tradition occupation modes, and after water extraction, because the soluble end of water is wide, can, by most of active ingredient stripping, medicine is more easily absorbed by the body, onset be faster, the form of medication such as such as decoction; Be used as medicine with former powder, the surface area of medicinal powder is larger, also active ingredient absorption in vivo in medicinal material is conducive to, but medicinal material un-extracted, active ingredient still needs stripping in vivo to absorb again, and the relative water extract of its onset is comparatively slow, but also weakens the toxicity that in medicinal material, harmful components cause human body simultaneously, be suitable for long-term taking, as former powder is prepared into the form of medication such as pill.At present in pharmacy procedure, ethanol extracts medicine as solvent, also be one of the most common extracting mode, ethanol is semi-polarity solvent, solubility property circle is between polarity and non-polar solven, some composition water miscible can be dissolved, also some compositions that non-polar solven dissolves can be dissolved, usually decocting is replaced with alcohol extract, thus avoid the stripping of a large amount of invalid components, improve concentration and the extraction efficiency of active ingredient, but comparatively water is expensive for the price of ethanol, in the large production of modern pharmaceutical industry, in order to save production cost, usually still based on decocting.When known compositions water extract of the present invention has physiologically active, demand during in order to adapt to various production and use, optionally water extraction, former powder, alcohol extracting or their combined method can prepare concrete formulation.
Present invention also offers above-mentioned food, health products or pharmaceutical composition and possess purposes in clearing heat and freeing strangury, the food of antibacterium or anti-inflammatory efficacy, health products or medicine in preparation.
Further, described bacterium is staphylococcus aureus, hemolytic streptococcus or Pseudomonas aeruginosa.
Research shows, the present composition can effectively suppress the bacteriums such as staphylococcus aureus, hemolytic streptococcus or Pseudomonas aeruginosa, there is good antibacterial and anti-inflammatory activity, can be used for treatment urinary system infection contamination etc. being belonged to the traditional Chinese medical science " heat is drenched " category disease, and present composition compatibility is precise and appropriate, played synergy, drug activity is obviously better than each single raw material.
Obviously, according to foregoing of the present invention, according to ordinary technical knowledge and the means of this area, not departing under the present invention's above-mentioned basic fundamental thought prerequisite, the amendment of other various ways, replacement or change can also be made.
Below by way of the form of specific embodiment, foregoing of the present invention is described in further detail again.But this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment.All technology realized based on foregoing of the present invention all belong to scope of the present invention.
Detailed description of the invention
The preparation of embodiment 1 present composition
Get cape jasmine 10g, field thistle 15g, lophatherum gracile 15g, Honeysuckle flower 10g, coix seed 15g, boiling 3 times, merge decocting liquid, filter, concentrated, add appropriate filler and granule (i.e. solid beverage) prepared by flavor enhancement.
The preparation of embodiment 2 present composition
Get cape jasmine 10g, field thistle 15g, lophatherum gracile 15g, Honeysuckle flower 10g, coix seed 15g, add water 60 DEG C of temperature leachings 3 times, merge leachate, filter, concentrated, add appropriate filler, be prepared into buccal tablet.
The preparation of embodiment 3 present composition
Get cape jasmine 10g, field thistle 15g, lophatherum gracile 15g, Honeysuckle flower 10g, coix seed 15g, add water 60 DEG C of ultrasonic extractions 3 times, merge extract, filter, concentrated, add appropriate flavouring, be prepared into beverage.
Beneficial effect of the present invention is illustrated below by way of test example.
Current known urinary tract infections etc. belong to the disease of the traditional Chinese medical science " heat is drenched " category, how to be caused by infected by microbes, therefore, effect of pharmaceutical composition clearing heat and freeing strangury of the present invention are described below by way of antibacterial, anti-inflammation test.
Test example 1 present composition efficacy test
1. optimum proportioning screening
1.1 experiment material
1.1.1 experimental drug
Test sample: cape jasmine, field thistle, lophatherum gracile, Honeysuckle flower, coix seed, believes medicine company purchased from Sichuan hundred, and quality meets the requirement of Pharmacopoeia of the People's Republic of China version in 2010; Positive reference substance: aspirin, believes medicine company purchased from Sichuan hundred, and quality meets two requirements of Pharmacopoeia of the People's Republic of China version in 2010; Negative controls: purified water, quality meets two requirements of Pharmacopoeia of the People's Republic of China version in 2010.
For determining optimum proportioning dosage, setting various dose proportioning group carries out Preliminary screening, is respectively:
Proportioning group 1 (cape jasmine: field thistle: lophatherum gracile: Honeysuckle flower: coix seed=1:1.5:1.5:1:1.5);
Proportioning group 2 (cape jasmine: field thistle: lophatherum gracile: Honeysuckle flower: coix seed=2:1:1.5:1:1.5);
Proportioning group 3 (cape jasmine: field thistle: lophatherum gracile: Honeysuckle flower: coix seed=1:1.5:2:1:1);
Proportioning group 4 (cape jasmine: field thistle: lophatherum gracile: Honeysuckle flower: coix seed=1:2:1:1:1.5).
Boiling simmer down to 100g crude drug in whole/100ml medicinal extract is for subsequent use respectively.
1.1.2 experiment reagent
Picric acid, dimethyl diaminophenazine chloride, dimethylbenzene, purified water.
1.1.3 laboratory apparatus
Yuyao gold promise TU10001B type electronic balance (d=0.1g); Germany Sartorius BS124S type electronic balance; TMS-1024i type automatic clinical chemistry analyzer; Card punch.
1.1.4 animal used as test
KM mouse, regular grade, body weight 18.0-22.0g, male and female half and half.Source: Da Shuo bio tech ltd, Chengdu.Production licence number: SCXK (river) 2008-24.
1.2. experimental technique
1.2.1 grouping
KM mouse 60, male and female half and half, body weight 18.0-22.0g, is divided into blank group, aspirin group, proportioning group 1, proportioning group 2, proportioning group 3, proportioning group 4 at random by body weight, totally 7 groups, often organizes 10.
1.2.2 administration
Method of administration: select consistent method of administration clinical in each tested material, gastric infusion.
Dosage: blank group (equal-volume purified water), aspirin group (1gkg
-1), proportioning group 1 (10gkg
-1), proportioning group 2 (10gkg
-1), proportioning group 3 (10gkg
-1), proportioning group 4 (10gkg
-1).Each Chinese drug-treated group dosage is all with crude drug gauge.
Administration volume: 10ml/kg.
Administration frequency and cycle: 1 times/day, totally 10 days.
1.2.3 modeling and detection
After last administration 1h, mouse left auricle two sides uniform application dimethylbenzene (0.05mL/ only), auris dextra is not painted with normal ear, after 30min, mouse is taken off cervical vertebra to put to death, left and right two ears under auricle edge scissor, are that the card punch of 7mm takes off round auricle in left and right sides ear same area with diameter, use scales/electronic balance weighing immediately, calculate auricle swelling degree, and calculate ear swelling inhibiting rate.Swelling=left auricle weight-auris dextra sheet weight; Ear swelling inhibiting rate %=(the average swelling of control group-average swelling of administration group) average swelling × 100% of/control group.
1.3. experimental result
Table 1 different Compatibility on Mice ear swelling degree, ear swelling inhibiting rate result
Note: administration group compares * P<0.05 with blank group, * * P<0.01, * * * P<0.001
Result of the test is in table 1, compare with blank group, each group medicine all effectively can reduce mice caused by dimethylbenzene xylene ear swelling (P<0.05, P<0.01, P<0.001), but proportioning group 1 act on compared with proportioning group 2,3,4 more excellent.
To sum up test, proportioning group 1 can the most effectively reduce mice caused by dimethylbenzene xylene ear swelling, has significant antiinflammatory action, therefore proportioning group 1 (cape jasmine: field thistle: lophatherum gracile: Honeysuckle flower: coix seed=1:1.5:1.5:1:1.5) is optimum dose proportion.
2. effect of pharmaceutical composition of the present invention and simple contrasts
2.1 experiment material
2.1.1 experimental drug
Test sample: cape jasmine, field thistle, lophatherum gracile, Honeysuckle flower, coix seed, believes medicine company purchased from Sichuan hundred, and quality meets the requirement of Pharmacopoeia of the People's Republic of China version in 2010; Positive reference substance: the root of large-flowered skullcap, believes medicine company purchased from Sichuan hundred, and quality meets the requirement of Pharmacopoeia of the People's Republic of China version in 2010; Negative controls: purified water, quality meets two requirements of Pharmacopoeia of the People's Republic of China version in 2010.
2.1.2 experiment reagent
Picric acid, dimethyl diaminophenazine chloride, purified water, dimethylbenzene, nutrient agar.
2.1.3 laboratory apparatus
DHP-9052 type electro-heating standing-temperature cultivator; LDZX-75KBS type autoclave; Clean work station; Thermostat water bath (Shanghai Ke Xi laboratory apparatus factory), Yuyao gold promise TU10001B type electronic balance (d=0.1g); Germany Sartorius BS124S type electronic balance; TMS-1024i type automatic clinical chemistry analyzer; Card punch.
2.1.4 experimental strain
Staphylococcus aureus, hemolytic streptococcus, Pseudomonas aeruginosa, be purchased from Nat'l Pharmaceutical & Biological Products Control Institute.
2.1.5 animal used as test
KM mouse, regular grade, body weight 18.0-22.0g, male and female half and half.Source: Da Shuo bio tech ltd, Chengdu.Production licence number: SCXK (river) 2008-24.
2.2. experimental technique
2.2.1 bacteriostatic experiment
Above-mentioned single medicinal material (cape jasmine, field thistle, lophatherum gracile, Honeysuckle flower, coix seed, the root of large-flowered skullcap) is added 10 times of water, slow fire boiling 2h, and filter, the liquid being concentrated into every milliliter contained 1g is for subsequent use.The another liquid this drug regimen being prepared into 2g crude drug/ml with method is 1g/ml, 0.5g/ml with sterile distilled water dilution.Get staphylococcus aureus, hemolytic streptococcus, Pseudomonas aeruginosa agar plate 18h culture, be made into 100,000,000/ml bacterium liquid with physiological saline for subsequent use.Get test organisms bacterium liquid with oese, evenly intensively coat agar plate, with the punching of aseptic 5mm aperture card punch, then every hole adds variable concentrations extract, and each liquid does two holes, to expiring hole (agar plate thickness 6mm).Lie against in 37 DEG C of incubators and cultivate 24h observed result, with bacterium region measurement antibacterial circle diameter completely not long around hole, record the mean value of each liquid holes antibacterial circle diameter.
2.2.2 anti-inflammation test
KM mouse 100, male and female half and half, body weight 18.0-22.0g, is divided at random by body weight, blank group (equal-volume purified water), aspirin group (1gkg
-1), compound high dose group (20gkg
-1), dosage group (10gkg in compound
-1), compound low dose group (5gkg
-1), cape jasmine group (10gkg
-1), field thistle group (10gkg
-1), lophatherum gracile group (10gkg
-1), Honeysuckle flower group (10gkg
-1), coix seed group (10gkg
-1), totally 10 groups, often organize 10.Administration volume: 10ml/kg.Administration frequency and cycle: 1 times/day, totally 10 days.
After last administration 1h, mouse left auricle two sides uniform application dimethylbenzene (0.05mL/ only), auris dextra is not painted with normal ear, after 30min, mouse is taken off cervical vertebra to put to death, left and right two ears under auricle edge scissor, are that the card punch of 7mm takes off round auricle in left and right sides ear same area with diameter, use scales/electronic balance weighing immediately, calculate auricle swelling degree, and calculate ear swelling inhibiting rate.Swelling=left auricle weight-auris dextra sheet weight; Ear swelling inhibiting rate %=(the average swelling of control group-average swelling of administration group) average swelling × 100% of/control group.
2.3. experimental result
2.3.1 bacteriostasis result
Inhibition zone measurement result is in table 1.
Table 1 inhibition zone measurement result
Note: each administration group compares * p<0.05**p<0.01 with control group
Table 1 shows, the positive drug root of large-flowered skullcap, and the high, medium and low dosage of compound all has fungistatic effect in various degree to several bacterium, is better than simple.
2.3.2 anti-inflammation test result
Table 2 pair mice ear degree, ear swelling inhibiting rate result
Note: administration group compares * P<0.05 with blank group, * * P<0.01, * * * P<0.001
Result of the test, in table 2, compares with blank group, and each group medicine all effectively can reduce mice caused by dimethylbenzene xylene ear swelling (P<0.05, P<0.01, P<0.001), but high, the middle dosage of compound is more excellent.
From the above results, the present composition is obviously better than each taste medicine and is used alone, and illustrates that each component of the present composition has the effect of Synergistic.
To sum up, the present composition all has inhibitory action to staphylococcus aureus, hemolytic streptococcus, Pseudomonas aeruginosa, also can effectively suppress mice caused by dimethylbenzene xylene ear thickness simultaneously, illustrate that the present composition has antibacterial, antiinflammatory action, can be used for supplemental treatment urinary tract infections.
Claims (8)
1. the food of clearing heat and freeing strangury, health products or a pharmaceutical composition, is characterized in that: its raw material is made up of the component of following weight proportion:
Cape jasmine 1 ~ 2 part, field thistle 1 ~ 2 part, lophatherum gracile 1 ~ 2 part, Honeysuckle flower 1 part, coix seed 1 ~ 1.5 part.
2. food according to claim 1, health products or pharmaceutical composition, is characterized in that: its raw material is made up of the component of following weight proportion:
Cape jasmine 1 part, field thistle 1.5 parts, lophatherum gracile 1.5 parts, Honeysuckle flower 1 part, coix seed 1.5 parts.
3. food according to claim 1 and 2, health products or pharmaceutical composition, it is characterized in that: it be by the medicinal powder of raw material, water extract or/and ethanol extract is active component, add the oral administration formulation that pharmaceutically conventional auxiliary material or complementary composition are prepared from.
4. food according to claim 3, health products or pharmaceutical composition, is characterized in that: described formulation is selected from oral liquid, beverage, granule, powder, pill, tablet or capsule.
5. the preparation method of food, health products or pharmaceutical composition described in Claims 1 to 4 any one, is characterized in that:
(1) raw material is taken by proportioning;
(2) by raw material extracting in water, Aqueous extracts is merged, preparation formulation.
6. preparation method according to claim 5, is characterized in that: in step (2), and described extracting method is selected from decoction, dipping or ultrasonic.
7. food, health products or pharmaceutical composition described in Claims 1 to 4 any one possess the purposes in clearing heat and freeing strangury, the food of antibacterium or anti-inflammatory efficacy, health products or medicine in preparation.
8. purposes according to claim 7, is characterized in that: described bacterium is staphylococcus aureus, hemolytic streptococcus or Pseudomonas aeruginosa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410472914.8A CN104207130B (en) | 2014-09-16 | 2014-09-16 | A kind of food of clearing heat and freeing strangury, health products or pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410472914.8A CN104207130B (en) | 2014-09-16 | 2014-09-16 | A kind of food of clearing heat and freeing strangury, health products or pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104207130A CN104207130A (en) | 2014-12-17 |
| CN104207130B true CN104207130B (en) | 2015-09-16 |
Family
ID=52089342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410472914.8A Active CN104207130B (en) | 2014-09-16 | 2014-09-16 | A kind of food of clearing heat and freeing strangury, health products or pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104207130B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110384772A (en) * | 2018-04-19 | 2019-10-29 | 雅安迅康药业有限公司 | A kind of pressed candy and application thereof improving damp-heat constitution |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101112594A (en) * | 2007-08-29 | 2008-01-30 | 北京艺信堂医药研究所 | Chinese traditional medicine compounding for treating diabetes urinary tract infection |
| CN101810803B (en) * | 2010-05-25 | 2011-11-09 | 泰一和浦（北京）中医药研究院有限公司 | Chinese medicinal composition for treating hematuria and use of prepared medicine |
| CN103656260A (en) * | 2012-09-17 | 2014-03-26 | 李承平 | Common cephalanoplos herb heat-clearing and strangury-freeing tablets |
-
2014
- 2014-09-16 CN CN201410472914.8A patent/CN104207130B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104207130A (en) | 2014-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101167811B (en) | External-applied preparation with anti-inflammation, itching-relieving and sterilization function and manufacturing method and application thereof | |
| US20090191288A1 (en) | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases | |
| US9662360B2 (en) | Treatment of herpes, pseudomonas, staph, and hepatitis | |
| CN102961469B (en) | Traditional Chinese medicine dispersible tablet for treating upper respiratory infection, and preparation method and quality detection method thereof | |
| CN102836228B (en) | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof | |
| CN108078975A (en) | Application of the pharmaceutical composition containing eucalyptol, limonene and australene in the drug for preparing treatment upper respiratory tract bacterium infection | |
| WO2011035734A1 (en) | Relinqing extract, preparative method and use thereof | |
| CN103961412B (en) | Traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN104069124B (en) | Compositions and preparation for gynecological infection | |
| CN104207130B (en) | A kind of food of clearing heat and freeing strangury, health products or pharmaceutical composition | |
| CN101095827A (en) | Chinese traditional medicine preparations for treating laryngopharynx disease and method for preparing the same | |
| CN108159017A (en) | A kind of Levofloxacin Hydrochloride Capsules and preparation method thereof | |
| CN104721241A (en) | Hibiscus rosa-sinensis flower bud extracts and application thereof | |
| CN105726631A (en) | Application of officinal magnolia bark extract to prepare medicine for treating cow mastitis | |
| CN103830469A (en) | Chinese medicinal composition for treating purulent meningitis and application thereof | |
| CN100435817C (en) | Medicine for treating rheumatism and rheumatoid diseases and preparing method | |
| CN103251845B (en) | For the compositions of cleaning throat and moistening larynx | |
| CN104815095A (en) | Composition with vaginal microecological balance repairing and recovering functions | |
| CN100486597C (en) | A pharmaceutical composition made from Chinese traditional medicine for treating snuffle, headache and preparation method thereof | |
| CN104352794A (en) | Traditional Chinese medicine preparation for treating lung yin deficiency type xerophthalmia | |
| CN104147007B (en) | A kind of for analgesic medical composition and its use | |
| CN108785383A (en) | A kind of antibacterial gynecology externally used pharmaceutical combination and the preparation method and application thereof | |
| CN103961654B (en) | A kind of White staphylococcus sheet and preparation method thereof | |
| CN109364148A (en) | A kind of FUKE QIANJIN PIAN and preparation method thereof | |
| CN102670807A (en) | Medicine composition for treating prostatitis and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |